$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Precautions and risk warnings after discontinuation of brigatinib/brigatinib (Embry)
2026-02-01 22:25:32
Check Details
What are the contraindications of ibrutinib/Eco and what should you pay attention to when using it?
2026-02-01 22:25:32
Check Details
Clinical trial status of Ruxolitinib Tablets/Jiekewei
2026-02-01 22:25:32
Check Details
Analysis of possible adverse reactions of Clofazimine
2026-02-01 22:25:32
Check Details
FDA accelerates approval of sevabertinib-Hyrnuo to treat non-squamous non-small cell lung cancer
2026-02-01 22:25:32
Check Details
Reasons Why Doctors May Not Recommend Patients to Use Axitinib (Inlida)
2026-02-01 22:25:32
Check Details
Whether trametinib (Megenin) needs to be taken for a long time and the risks of long-term use
2026-02-01 22:25:32
Check Details
Is Avatrombopag a domestic or imported drug and its market comparison?
2026-02-01 22:25:32
Check Details
Do patients with different types of leukemia need to take giritinib (segatan)?
2026-02-01 22:25:32
Check Details
Whether the hospital can be reimbursed for purchasing Osimertinib (Tagrisso) and the process description
2026-02-01 22:25:32
Check Details
How long does it take to take Eltrombopag (Revlan) before platelets can be significantly increased?
2026-02-01 22:25:32
Check Details
Differences in names and usage between loplastin (Huierning) and romilastin
2026-02-01 22:25:32
Check Details
1
2
...
2321
2322
2323
2324
2325
2326
2327
...
10228
10229
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Asciminib (Scemblix): Targeted Mechanism, Dosing Regimens, and Missed-Dose Guidance
2
Vigabatrin (Sabril): Mechanism of Action, Pharmacokinetics, and Safety Monitoring
3
Belzutifan (WELIREG) Treatment Guide: Duration, Onset of Action, and Monitoring Protocol
4
Lapatinib Side Effects: Managing Diarrhea, Skin Reactions, and Liver Function Changes
5
Trelagliptin: A Once-Weekly Long-Acting Oral DPP-4 Inhibitor
6
Neurokinin Receptor Antagonists: A Non-Hormonal Approach to Menopausal Hot Flashes and Sleep Disturbances
7
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
8
Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression
9
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
10
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
11
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
12
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management